

<b>File reference</b>	W18FOI158
<b>Key words</b>	Psoriasis and First Advanced Therapy
<b>Date of release</b>	20/08/2018
<b>Attachments</b>	No

## Freedom of Information Act Disclosure log - Reply Extract

You asked

**1. Within your Trust and over the last three months, how many Psoriasis [PsO] patients have been initiated on their first advanced therapy (i.e. Biologic, Apremilast or Dimethyl fumarate)?**

Although Pharmacy can identify the number of patients receiving each of the medications described below that are prescribed by dermatology we cannot;

- Claim these are exclusively for Psoriasis (although this is the only dermatology indication for most of them)
- Identify whether these patients have had other advanced treatments for this indication previously

**2. Total New Advanced Therapy patient Initiations.**

Where possible please split by treatment;

**Adalimumab [Humira]**

**Apremilast [Otezla]**

**Brodalumab [Kyntheum]**

**Certolizumab [Cimzia]**

**Dimethyl fumarate [Skilarence]**

**Etanercept [Enbrel]**

**Etanercept Biosimilar**

**Guselkumab [Tremfya]**

**Infliximab [Remicade]**

**Infliximab Biosimilar**

**Ixekizumab [Taltz]**

**Secukinumab [Cosentyx]**

**Ustekinumab [Stelara]**

Not applicable

**Attachments included:** No